Literature DB >> 8142641

Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia.

A Keating1, X H Wang, P Laraya.   

Abstract

Recent studies suggest that the BCR-ABL gene plays a critical role in the pathogenesis of Ph+ chronic myeloid leukemia (CML). We investigated the hematopoietic colonies derived from the marrows of 12 patients with Ph+ CML in chronic phase by reverse transcriptase-polymerase chain reaction (RT-PCR) amplification of BCR-ABL mRNA and by cytogenetics. Colonies were individually harvested and each colony divided into two portions, one for cytogenetics and the other for isolation of total RNA for PCR of BCR-ABL transcripts and for an RNA internal control. We found that 23% +/- 18% (mean +/- SD, range 0% to 60%) of Ph+ colonies did not transcribe the aberrant gene. In each case when BCR-ABL transcription was not detected, normal ABL mRNA was present. The data suggest that hitherto unknown mechanisms may regulate BCR-ABL expression in some Ph+ cells and indicate that caution should be exercised in the interpretation of results using RT-PCR analysis of hematopoietic colonies from clinical specimens and from experiments with antisense oligonucleotides directed at the BCR-ABL gene. These data also raise the notion of a transitional Ph+ precursor cell in which BCR-ABL may become upregulated and lead to a fully expressed phenotype. We conclude that further studies correlating the frequency of Ph+ PCR- progenitors with prognostic clinical variables are warranted.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142641

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.

Authors:  Jean-Claude Chomel; Marie-Laure Bonnet; Nathalie Sorel; Angelina Bertrand; Marie-Claude Meunier; Serge Fichelson; Michael Melkus; Annelise Bennaceur-Griscelli; François Guilhot; Ali G Turhan
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

2.  Evolutionary dynamics of chronic myeloid leukemia.

Authors:  David Dingli; Arne Traulsen; Tom Lenaerts; Jorge M Pacheco
Journal:  Genes Cancer       Date:  2010-04

3.  SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.

Authors:  Olga Frolova; Juliana Benito; Chris Brooks; Rui-Yu Wang; Borys Korchin; Eric K Rowinsky; Jorge Cortes; Hagop Kantarjian; Michael Andreeff; Arthur E Frankel; Marina Konopleva
Journal:  Br J Haematol       Date:  2014-06-19       Impact factor: 6.998

4.  Correlation between BCR-ABL expression and tumor burden is restricted to the transition from minor to major cytogenetic response in interferon treated CML patients.

Authors:  László Kereskai; János A Vass; Mária Kneif; László Pajor
Journal:  Pathol Oncol Res       Date:  2003-10-07       Impact factor: 3.201

5.  Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.

Authors:  Jean-Claude Chomel; Ali G Turhan
Journal:  Oncotarget       Date:  2011-09

6.  A stochastic model of oncogene expression and the relevance of this model to cancer therapy.

Authors:  Francis D Alfano
Journal:  Theor Biol Med Model       Date:  2006-01-31       Impact factor: 2.432

7.  Plasma levels of norepinephrine and expression levels of ß2-adrenergic receptor gene correlate with the incidence of acute graft-versus-host disease.

Authors:  Zahra Momeni-Varposhti; Mohammad Hossein Kazemi; Mehdi Talebi; Rouzbeh Chegeni; Elham Roshandel; Abbas Hajifathali; Ali Akbar Movassaghpour
Journal:  Med J Islam Repub Iran       Date:  2020-11-09

8.  Pretreatment evaluation of fluorescence resonance energy transfer-based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib.

Authors:  Takeshi Kondo; Mari Fujioka; Masumi Tsuda; Kazunori Murai; Kohei Yamaguchi; Takuto Miyagishima; Motohiro Shindo; Takahiro Nagashima; Kentaro Wakasa; Nozomu Fujimoto; Satoshi Yamamoto; Masakatsu Yonezumi; Souichi Saito; Shinji Sato; Kazuei Ogawa; Takaaki Chou; Reiko Watanabe; Yuichi Kato; Shuichiro Takahashi; Yoshiaki Okano; Joji Yamamoto; Masatsugu Ohta; Hiroaki Iijima; Koji Oba; Satoshi Kishino; Junichi Sakamoto; Yoji Ishida; Yusuke Ohba; Takanori Teshima
Journal:  Cancer Sci       Date:  2018-05-29       Impact factor: 6.716

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.